In a phase 3 trial of 525 Chinese participants with moderate to severe COPD, nebulised ensifentrine improved FEV1 AUC 0–12 h vs placebo by 110 mL (95% CI 69–151) over 24 weeks, with similar adverse event rates.
RCTn = 525
Zhou et al. Efficacy and Safety of Ensifentrine in Chinese Participants With COPD: The ENHANCE-CHINA Randomized Clinical Trial